As of December 31, 2024, LAVA had cash, cash equivalents, and investments of $76.6 million, compared to cash, cash equivalents, and investments of $95.6 million as of December 31, 2023. The Company believes its current cash, cash equivalents and investments will be sufficient to fund operations into 2027.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LVTX:
- LVTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cautious Stance on LAVA Therapeutics Amid Strategic Review and Workforce Reduction
- Lava Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Lava Therapeutics implements restructuring plan, workforce reduction of 30%
- LAVA Therapeutics Announces Restructuring Plan for 2025